Tabletted medical product (versions)

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and concerns preparation of a solid dosage form for treating respiratory allergosis and arresting nasopharynx edema. There is offered a tableted medical product containing mixed active substance and excipient. As an active substance, it contains a corticosteroid preparation, and according to the invention, additionally contains an active substance presented with adrenaline or noradrenaline. The inside of a tablet contains the corticosteroid preparation, while the exterior contains adrenaline. As a corticosteroid preparation it contains dexamethasone, prednisolone or celestone. Also there is offered a tableted medical product that contains mixed active substance and excipient. As an active substance, it contains a corticosteroid preparation, and additionally contains active substances presented with adrenaline or noradrenaline, and also aminophylline and mesatone. The tablet is multilayered, its inside contains mesatone, the layer containing aminophylline adjoins the inside, then the layer containing the corticosteroid preparation is executed, and the exterior contains adrenaline or noradrenaline.

EFFECT: there is offered a tableted medical product.

4 cl, 3 ex

 

The invention relates to pharmaceutical industry and for the production of solid dosage forms for the treatment of respiratory allergies and edema swelling of the nasopharynx.

Known tablets medicine containing the active drug with filler. On tablets deposited film coating of a mixture of methylcellulose-8, titanium dioxide and tropeolin at a ratio of one tablet, wt.%: 63,80:33,60:2,60. To obtain a drug active drug is mixed with a filler consisting of a mixture of sugar, milk and potato starch at a ratio of one tablet, wt.%: 50,00:1,00 (RF patent No. 2123330, CL AC 9/20, 1998).

Performing a film coating complicates the process of cooking tools.

Known drug - polcortolon with antiallergic, antipruritic and anti-inflammatory effect, including an active agent and filler. As active substances the product contains triamcinolone 4 mg in one pill, the filler is lactose, potato starch, magnesium stearate (Reference VIDAL - drugs in Kazakhstan. - M.: Attraversare, 2005, s.293).

This tool is not a high activity as pharmacological action of the drug develops within 1-2 hours after administration.

<> The objective of the invention is to develop a tablet medicines for the treatment of respiratory allergies and edema swelling of the nasopharynx.

The achieved result is an increase in the activity of the medicinal product, as well as the expansion of the range of antiallergic drugs.

To do this, preformed medicinal product, comprising a mixture of active substances and fillers according to the invention the active substance is adrenaline or noradrenaline content in one tablet of 0.2-1.0 mg of epinephrine or 0.5-2.0 mg of norepinephrine.

Tablets drug according to the second variant of the invention, comprising a mixture of active substance and the excipient, the active substances it contains a corticosteroid drug, according to the invention additionally contains an active substance, which serves as adrenaline or noradrenaline, while the inner part of the tablet includes a corticosteroid medication in the amount of 2.0 to 10.0 mg, and the outer part consists of adrenaline in the amount of 0.2-1.0 mg of epinephrine or 0.5-2.0 mg of norepinephrine.

As a corticosteroid drug it contains dexamethasone, prednisolone or Celeste.

Tableted medication in accordance with the third variant of the invention, comprising a mixture of active substances and fill the La, at the same time as the active substance it contains a corticosteroid drug, according to the invention additionally contains active substances that serve as adrenaline or noradrenaline, as well as aminophylline and mezaton, this tablet is made of layered, the inner part of the tablet includes mezaton in the amount of 2.0 to 10.0 mg, to the interior of the adjacent layer containing aminophylline in the amount of 0.2-0.5 g, then made a layer containing a corticosteroid medication in the amount of 2.0 to 10.0 mg, and the outer layer includes adrenaline or noradrenaline.

As a corticosteroid drug it contains dexamethasone, prednisolone or Celeste.

The inclusion of each of the variants of the medicinal product active substance in the form of adrenaline or noradrenaline can effectively treat respiratory allergies and quickly to stop the swelling of the nasopharynx when the resorption of funds in the mouth.

The content in one tablet of 0.2-1.0 mg of epinephrine or 0.5-2.0 mg of norepinephrine is optimal to reduce swelling.

The second and third variants of the claimed medicinal product intended for more severe cases, when using epinephrine or norepinephrine unable to arrest the swelling.

When reducing the content of each of the components is below the minimum stated pharmacological activity of cf is DSTV is insufficient for treatment, and the increase in the number of active substances more than the maximum stated impractical because it cannot be excluded drug overdose. Therefore, the specified number of each of the active substances is optimal.

As filler can be used any known fillers, such as lactose, starch, magnesium stearate.

Example 1. Prepare the drug by mixing powder of adrenaline or noradrenaline with filler, such as potato starch and/or sugar in the mixer, the resulting mixture is moistened with purified water dispense to obtain tablets, each of which contains from 0.2 to 1.0 mg of epinephrine or 0.5-2.0 mg of norepinephrine and granularit. The granules are dried in the dryer, and then pressed into tablets. The ratio of the active substance and the filler is 1:3-1:5.

For the treatment of respiratory allergies and edema swelling of the nasopharynx put the pill in his mouth. In its dissolution adrenaline or noradrenaline absorbed in the mucous membrane of the mouth and causes narrowing of the blood vessels of the mucous membranes of the bronchi. Mild edema occurs in 5-10 minutes.

Example 2. In the manufacture of tablets, including several active components, first, similarly form a billet inner part of the tablet, on which is includes a corticosteroid medication in the amount of 2.0 to 10.0 mg, after pressing the workpiece it is covered with a mixture of filler with epinephrine in the amount of 0.2-1.0 mg or norepinephrine in the amount of 0.5 to 2.0 mg Ratio of the active substance and filler for all segments of the tablet may be in the range of 1:3-1:5. This tool is used for edema swelling of the nasopharynx in patients with severe respiratory allergies.

Example 3. The medicine in accordance with a third variant of the invention prepared according to example 2, but the inner part of the tablet form of mezatona in the amount of 2.0 to 10.0 mg, to the interior of the adjacent layer containing aminophylline in the amount of 0.2-0.5 g, then made a layer containing a corticosteroid medication in the amount of 2.0 to 10.0 mg, and the outer layer includes adrenaline or noradrenaline.

As a corticosteroid drug it contains dexamethasone, prednisolone or Celeste.

The advantage of the proposed variants of the medicinal product is ease of use, as well as its storage and transport.

While the pharmaceutical effectiveness of the tools is very high, because you are a direct impact on the fabric of the nasopharynx when the resorption of the drug in the mouth.

1. Tablets drug, comprising a mixture of active substances and fillers, as active in the society it contains a corticosteroid drug, characterized in that it additionally contains an active substance, which serves as adrenaline or noradrenaline, while the inner part of the tablet includes a corticosteroid medication in the amount of 2.0 to 10.0 mg, and the outer part consists of adrenaline in the amount of 0.2-1.0 mg of epinephrine or 0.5-2.0 mg of norepinephrine.

2. Tablets drug according to claim 2, characterized in that as a corticosteroid drug it contains dexamethasone, prednisolone or Celeste.

3. Tablets drug, comprising a mixture of active substance and the excipient, the active substances it contains a corticosteroid drug, characterized in that it additionally contains active substances that serve as adrenaline or noradrenaline, as well as aminophylline and mezaton, this tablet is made of layered, the inner part of the tablet includes mezaton in the amount of 2.0 to 10.0 mg, to the interior of the adjacent layer containing aminophylline in the amount of 0.2-0.5 g, then made a layer containing a corticosteroid medication in the amount of 2.0 to 10.0 mg, and the outer layer includes adrenaline or noradrenaline.

4. Tablets drug according to claim 4, characterized in that as a corticosteroid drug it contains dexamethasone, prednisolone or Celeste.



 

Same patents:

FIELD: medicine.

SUBSTANCE: external skin preparation contains as active components a ferrous compound and a compound chosen from 5-aminolevulin acid, salt of 5-aminolevulin acid, ester of 5-aminolevulin acids, ester of salt of 5-aminolevulin acids, N-acyl-5-aminolevulin acids, salts of N-acyl-5 aminolevulin acid and ester of N-acyl-5-aminolevulin acid. The ferrous compound is chosen from iron (II) citrate, sodium-iron citrate, ammonium-iron citrate, iron acetate, iron oxalate, iron (II) succinate, sodium-iron succinate and citrate, iron (II) pyrophosphate, iron (III) pyrophosphate, heme iron, iron dextrane, iron lactate, iron (II) gluconate, sodium-iron diethylene triaminepentaacetate, ammonium-iron diethylene triaminepentaacetate, ethylenediaminetetraacetate sodium-iron ethylene aminpentaacetate, ammonium-iron ethylene aminpentaacetate, iron triethylene tetraamine, sodium-iron dicarboxymehtyl glutamate and ammonium-iron dicarboxymehtyl glutamate.

EFFECT: improved skin look, prevention or reduction of roughness, dryness, wrinkles, flabbiness, and pigment spots, efficient for atopic dermatitis.

16 cl, 2 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: there is described thiomorpholine compound presented by formula (I) wherein the ring A represents benzene ring; the ring B represents benzene ring; R1 represents hydrogen atom, R2 represents C1-6-alkyl group; R3a and R3b are identical or different, each representing hydrogen atom or C1-6-alkyl group, and n represents an integer equal to 2, or its pharmaceutically acceptable salt. There is also described method for making the compound of formula (1), a pharmaceutical composition and application of the compound of formula (1) for making a medical product used for treatment and prevention of the disease chosen from inflammation, allergic diseases, pain, migraine, neuralgia, itch, cough, central nervous system diseases, alimentary organ diseases, nausea, vomiting and urological disorders.

EFFECT: compounds exhibits affinity to neurokinine-1 receptor.

6 cl, 4 tbl, 16 ex

FIELD: medicine.

SUBSTANCE: invention refers to compounds of formula I or formula II, to their pharmaceutically acceptable salts, enantiomers and diastereoisomers as metalloprotease inhibitors, and also to a pharmaceutical composition based thereon and to versions of application thereof. Said compounds can find application in treatment of the diseases mediated by activity of metalloproteases, Her-2 SHEDDASE, ADAM-10 and ADAM-17, such as arthritis, cancer, cardiovascular disorders, skin diseases, inflammatory and allergic conditions, etc. In general formula I or II: A represents CWNHOH; B represents CH2; G represents CH2; D represents oxygen; X represents CH2NRb; Y represents CH2; M represents C; U is absent or represents NRb; V is absent or represents phenyl, or 4-10-members heterocyclyl containing 1-2 heteroatoms chosen from N and S, substituted with 0-5 groups Re; U' is absent or represents C1-10alkylene, O or combinations thereof; V' represents H, C1-8alkyl, NRbRc, C6-10carbocyclyl substituted with 0-3 groups Re, or 5-14-members heterocyclyl containing 1-3 heteroatoms chosen from N, O and C substituted with 0-4 groups Re; Ra and Re, independently represents H, T, C1-8alkylene-T, C(O)NRa'(CRb'Rc')r-T, (CRb'Rc')r-O-(CRb'Rc')r-T, OH, Cl, F, CN, NO2, NRIRII, COORIV, ORIV, CONRIRII, C1-8halogenalkyl, C3-13carbocyclyl; Rb and Rc independently represents H, T, C1-6alkylene-T, C(O)O(CRb'Rc')r-T, C(O)(CRb'Rc')r-T, S(O)p(CRb'Rc')r-T; T represents H, C1-10alkyl substituted with 0-1 groups Rb'; C3-6carbocyclyl, 5-6-members heterocyclyl containing one oxygen atom; Ra' Rb' and Rc' independently represents H, ORIV or phenyl; R1 represents hydrogen; R2 represents hydrogen; R3 represents: (i) C1-10alkyl; (ii) 4-14-members heterocyclyl containing 1-3 nitrogen atoms optionally substituted with one or two substitutes chosen from C1-6alkyl, OR13, 5-10-members heterocyclyl containing 1-3 heteroatoms chosen from N O and C, or phenyl; (iii) NR16R17; R4 represents H; R4' represents H; R5' represents H; W represents oxygen; R13 represents C1-C6alkyl; R16 and R17 independently represents C1-C10alkyl or phenyl where each is optionally substituted with one C1-4alkyl; RI and RIIindependently represents H or C1-6alkyl; RIV represents C1-6alkyl; i is equal to 0; p is equal to 1 or 2 and r is equal to 0, 1 or 2; provided that a) a spiro ring represents a stable chemical base unit and b) NR8 and NRb do not contain neither N-N, nor N-O bonds.

EFFECT: higher efficiency of the composition and method of treatment.

54 cl, 1 tbl, 9 dwg, 284 ex

FIELD: chemistry.

SUBSTANCE: proposed phosphodiesterase 4 inhibitors are characterised by formulae II, III, V, VI, where X is CH or N; L is a single bond, -(CH2)nCONH-, -(CH2)nCON(CH2CH3)-, (CH2)nSO2, (CH2)nCO2 or alkylene, optionally substituted oxo or hydroxy; n assumes values from 0 to 3; R1 is optionally substituted alkyl; R3 - H, alkyl, cycloalkyl, alkoxyalkyl, optionally substituted phenyl, phenylalkyl, heterocyclyl, heterocyclylalkyl or cycloalkylalkyl; R4 and R5 represent alkyl; R6 - cycloalkyl, R7 is H; R8 is H, carboxy, alkoxycarbonyl, -CO-alkyl, optionally substituted alkyl.

EFFECT: new phosphodiesterase 4 inhibitors have improved properties.

55 cl, 30 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, particularly a preparation that is able to suppress an immune response underlying immunoglobulin-E-dependent allergic diseases. Application of water-soluble polysaccharides made of clover (Trifolium pretense L.), as a preparation able to suppress the immune response underlying immunoglobulin-E- dependent allergic diseases.

EFFECT: polysaccharides made of clover (Trifolium pretense L) exhibit effective antiallergic activity and affect the earliest stages of formation of Th2-dependent allergic reactions associated with development of immunoglobulins E and G1.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry and concerns pharmaceutical composition for prevention and treatment of diseases and disease states connected with metabolic pathways of cycloxygenase-2 (CG-2) and 5-lipooxygenase (5-LO), which contains mixture of extract obtained from Scutellariae and enriched with flavonoids with free B-ring, which include baicalein, and extract obtained from Acacia and enriched with flavans, which include catechine and epicatechine. Claimed invention also relates to method of body weight loss and control over glucose level in blood. Methods by claimed invention include introduction to person, who needs it, of efficient amount of composition by claimed invention together with pharmaceutically acceptable carrier. Claimed invention mainly relates to prevention and treatment of diseases and states connected with metabolic pathways of cycloxygenase-2 (CG-2) and 5-lipooxygenase (5-LO), including, but not confining to it, stopping discomfort and pain in joints, induced by such states as osteoarthritis, rheumatoid arthritis and other injuries caused by overload.

EFFECT: composition possesses high efficiency.

35 cl, 22 ex, 15 tbl

FIELD: chemistry.

SUBSTANCE: present invention relates to novel methods (versions) of producing N-acyl derivatives of amino acids of general formula , where n equals 2 or 3; and R is or their salts, using anhydrides of glutaric or succinic acid.

EFFECT: advantages of the proposed methods lie in simplicity of their realisation, easy extraction of the end product and high output of the end products.

2 cl, 27 tbl, 22 ex

FIELD: chemistry.

SUBSTANCE: invention relates to 4-{[1-(aminocarbonyl)-4-piperidinyl]amino}-H-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazole[3,4-b]pyridine-5-carboxamide, which is a compound of formula or its pharmaceutically acceptable salt, as well as to a method of producing said compounds. The invention also relates to use of the said compound or its pharmaceutically acceptable salt as phosphodiesterase IV (PDE4) inhibitor, for example in treatment and/or prevention of inflammatory and/or allergic disease, cognitive impairment or depression in mammals. The invention particularly pertains to use of the compound or its pharmaceutically acceptable salt in treating and/or preventing atopic dermatitis in mammals, for example via external local administration to a mammal, for example a human being.

EFFECT: pharmaceutical compositions are also provided, which contain the said compound or its pharmaceutically acceptable salt, particularly suitable for external local administration.

35 cl, 1 tbl, 19 ex

Antiallergic agent // 2378004

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, particularly an agent able to inhibit immune response underlying immunoglobulin-E-dependent allergic diseases. Application of water-soluble polysaccharides made of Acorns calamus L. root, as an agent able to inhibit immune response underlying immunoglobulin-E-dependent allergic diseases.

EFFECT: said polysaccharides made of Acorns calamus L root are able to inhibit the first-stage development of immunoglobulin-E-dependent allergies that cause reduced synthesis of immunoglobulins classes E and G1 that ensures inhibition of further events related to development and release of biologically active substances taking a damaging action on cells and tissues.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: new compounds of thienopyrazole are described with formula (1) , where R1 means non-substituted C3-C8-cycloalkyl group or tetrahydropyranyl, R2 means non-substituted C1-C3alkyl group, R3 means atom of hydrogen, R4 means various groups mentioned in invention formula. Compounds inhibit PDE 7 and, accordingly, increase cell level of cyclic adenosine monophosphate. Pharmaceutical composition is also described, as well as method for inhibition of PDE, methods for production of compound with formula (1), where R4 means CO2R7, and intermediate compounds.

EFFECT: possibility to use for treatment of various types of such diseases as allergic diseases, inflammatory diseases or immunological diseases.

20 cl, 138 tbl, 440 ex

FIELD: medicine.

SUBSTANCE: solid unit dosage form with enterosoluble coating contains pharmacologically effective amount of mycophenolic acid or mycophenolate and pharmaceutically acceptable additives, where mycophenolic acid or mycophenolate are found practically in an anhydrous form in amount approximately 20 to approximately 95% on total basis of solid unit dosage form with the enterosoluble coating. There is also offered method for preparing the solid unit dosage form containing practically anhydrous mycophenolic acid or its salt.

EFFECT: high efficiency and improved storage-stability of the composition.

12 cl, 4 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical unit dosage form for treatment or prevention of cardiovascular episodes contains therapeutic amount of: antagonist of β-adrenergic receptor, diuretic or both; an agent lowering cholesterol level; an inhibitor of renin-angiotensin system; and aspirin. The pharmaceutical unit dosage form can be made in a two-layered tableted form. The first layer thereof contains simvastatin and aspirin, the second layer contains athenolol and lisinopril, or the second layer contains hydrichlorothiazide and lisinopril.

EFFECT: according to the invention pharmaceutical unit dosage form combines a number of drugs for oral intake once a day that improves compliance by the patient with prescribed regimen due to elimination of inconveniences related to intake of several doses of drugs during the day, and reduces probability of missing the dose.

24 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products and concerns method for making solid oral pharmaceutical composition containing a hydrophilised form of 5-chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophencarboxaime (I), differing that at first by spraying granulation, a granulated material is prepared. It contains a hydrophilised form of active substance (I). Then said granulated material if necessary is transformed into a pharmaceutical composition with pharmaceutically acceptable additives added.

EFFECT: method allows improving biological availability of the active substance.

6 cl, 2 tbl, 5 ex

Solid dosage form // 2377987

FIELD: medicine.

SUBSTANCE: present invention refers to medical products, particularly to a solid dosage form, containing an active substance from the group of inhibitor monoamine neurotransmitter uptake inhibitors with 2 3-two-substituted tropane skeleton of formula (1) which is produced by spaying a solution of the active substance over the carrier and containing the following components: 0.01-5.00 wt % of the active substance, 80.00-95.00 wt % of one or more carriers chosen from the group including carbohydrates and binding agents, providing binding of the components in a dry state, 1.00-10.00 wt % of one or more adjuvants chosen from the group, including cellulose derivative and salts of fatty acids, 0-10.00 wt % of a film coating mainly containing one or more filming agents, one or more elasticity improving substances, one or more pigments and optionally one or more dyes. Besides the inventions concern the method for making said dosage form and application thereof.

EFFECT: said dosage form expresses improved uniformity of the active substance, stability and biocompatibility.

17 cl, 2 dwg, 6 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: there is offered application of L-tryptophan and L-tryptophan peripheral decomposition inhibitor (preferentially, carbidopa or Benserazide) for making a medicinal agent for prevention or treatment of pain, depression, somnipathy and other serotonin-dependent diseases of central nervous system (CNS) with L-tryptophan being presented by a slow-release drug, and L-tryptophan peripheral decomposition inhibitor - by a fast-release drug.

EFFECT: there is assured constant high concentration of tryptophan in the patient's blood plasma with the real absence of by-effects following administration of the declared combination.

5 cl, 2 dwg, 2 ex

FIELD: food industry.

SUBSTANCE: invention refers to confectionary industry. Chewing confectionary composition contains from 0.1 to 3 % of weight of enzyme, solid material of base, sweetener not provoking caries, substance stabilising enzymes and water below 5% of weight. Enzyme is chosen from proteases extracted from fruit products and is introduced into solid material of composition base at temperature 80°C, also enzyme activity of proteases is maintained in the composition at least for 4 weeks at 23°C.

EFFECT: introduction of enzyme into composition facilitates destructing of dental deposit, prevents its formation and adhesion on teeth surface at product consumption.

13 cl, 7 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: present invention concerns medical products, particularly a tableted solid veterinary-medical compound containing a pharmaceutical active raw material (particularly enrofloxacin, pradofloxacin) 0.001 to 90 wt %, a flavouring and/or aromatic substance representing Bayopal and Artificial Beef Flavor, in amount 5% to 15% in terms of total mass of ready compound and at least 1.5 wt %, and no more than 15 wt % of fine-grained silicon dioxide in terms of total mass of ready compound, and one or more adjuvants.

EFFECT: such qualitative and quantitative composition of tablets provides comprehensible flavouring properties thereof with preserving pharmaceutical properties (particularly solidity).

3 cl, 10 dwg, 9 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular to pharmaceutics, and concerns pharmaceutical compositions, which contain as active substance therapeutically effective quantity of ladasten, and as target additives - starch, stearic acid and/or its salt or ludipress and stearic acid and/or its salt with definite ratio of said components. Composition is made in form of pills, contains optimal quantity of target additives, which allows to obtain easy swallowed pills. Pills meet all requirements of State Pharmacopoeia XI edition.

EFFECT: medication form easily releases active substance, which provides its high bioaccessibility.

13 cl, 1 tbl, 5 ex

Sweetening agent // 2376886

FIELD: food industry.

SUBSTANCE: invention relates to chemical and pharmaceutical industry and concerns production of sweeteners containing stevioside. Stevioside is mixed with lactose, sodium carboxy-methylcellulose and leucine and produced in form of tabs by direct pressing on rotary tablet press.

EFFECT: obtained tabs of food sweetener have improved stability while storaging.

4 ex, 7 tbl

FIELD: medicine.

SUBSTANCE: invention is related to chemical-pharmaceutical industry, namely to agents on vegetal basis, intended for intake together with food or drinks to facilitate consequences and reduce period of alcoholic intoxication of human body (withdrawal syndrome). Agent for reduction of alcoholic intoxication period contains active and auxiliary substances, besides active substances used are dry extracts of ginger, eleutherococcus, ginseng, paullinia and holly at the following ratio of components, wt %: dry extract of ginger 40-60; dry extract of eleutherococcus 14-28; dry extract of ginseng 2.0-6.0; dry extract of paullinia 5.0-9.0; dry extract of holly 0.5-2.5; auxiliary substances - the rest. Auxiliary substances used are mainly represented by citric acid, succinic acid, dry extract of licorice.

EFFECT: intake of agent is registered with significant reduction or complete absence of thirst, nausea, dizziness, fatigue, coordination disorder, headache.

3 cl

FIELD: medicine.

SUBSTANCE: for treating broncho-obstructive syndrome combined with pneumonia and tracheobronchitis in newborns, nebuliser inhalations with oxygen supplement 30-60% one session of which consists in consistent introduction of Salbutamol and Budesonid. The initial dose includes 0.15 mg/kg of Salbutamol and 0.125 mg of Budesonid - 2-3 sessions a day. The stabilisation requires 0.15 mg/kg of Salbutamol and 0.25-0.3 mg/kg of Budesonid once a day. The therapeutic course is 3-14 days.

EFFECT: method allows improving respiratory pulmonary function, reducing symptoms of respiratory insufficiency, relieving severity and duration of infectious-inflammatory process in airways.

8 tbl, 2 ex

Up!